NCT04265872View on ClinicalTrials.gov

Bortezomib Followed by Pembrolizumab and Cisplatin in metTNBC

EARLY_PHASE1RecruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

October 15, 2020

Primary Completion Date

December 31, 2025

Study Completion Date

March 31, 2026

Conditions
Breast Cancer
Interventions
DRUG

Bortezomib; pembrolizumab and cisplatin injections--bortezomib followed by pembro/cis

injection into a vein

Trial Locations (1)

75246

RECRUITING

Baylor University Medical Center, Baylor Charles A Sammons Cancer Center, Dallas

Sponsors
All Listed Sponsors
lead

Baylor Research Institute

OTHER